A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod (FLUENT)


Relapsing Multiple Sclerosis



ClinicalTrials.gov identifier


Novartis reference number



Phase 4

This study is Recruiting.

Official title

A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]


A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod

Contacts and locations

Novartis contact

Novartis Pharmaceuticals 1-888-669-6682

United States

  • Novartis Investigative Site
    Cullman , Alabama , United States , 35058
  • Novartis Investigative Site
    Basalt , Colorado , United States , 81621
  • Novartis Investigative Site
    Hartford , Connecticut , United States , 06112
  • Novartis Investigative Site
    Overland Park , Kansas , United States , 66210
  • Novartis Investigative Site
    Buffalo , New York , United States , 14209
  • Novartis Investigative Site
    Knoxville , Tennessee , United States , 37920

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About cookies page.